Status:
RECRUITING
68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers
Lead Sponsor:
The First Affiliated Hospital of Xiamen University
Conditions:
Tumor
PD-L1
Eligibility:
All Genders
18-90 years
Brief Summary
To evaluate the potential usefulness of 68Ga-NK224 positron emission tomography/computed tomography (PET/CT) for the evaluation of PD-L1 expression in primary and/or metastatic tumors, compared with h...
Detailed Description
Participants with cancer underwent 68Ga-NK224 PET/CT for an initial assessment. Tumor uptake was quantified by the maximum standard uptake value (SUVmax) and mean SUV (SUVmean). In addition, the PD-L1...
Eligibility Criteria
Inclusion Criteria:
- (i) adult patients (aged 18 years or order);
- (ii) patients with newly diagnosed or previously treated malignant tumors (supporting evidence may include magnetic resonance imaging (MRI), CT, tumor markers and pathology report);
- (iii) patients who had scheduled 68Ga-NK224 PET/CT scans;
- (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Exclusion Criteria:
- (i) patients with non-malignant lesions;
- (ii) patients with pregnancy;
- (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Key Trial Info
Start Date :
December 31 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06754345
Start Date
December 31 2023
End Date
December 31 2026
Last Update
March 31 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China, 361000